Compare Stocks: RLAY, ASND, BBIO, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$237.59 +0.4%	$254.83	$186.05 ▼ $282.15	$14.82B	0.35	694,892 shs	806,919 shs
BBIO BridgeBio Pharma	$66.58 0.0%	$79.31	$48.78 ▼ $93.42	$13.02B	0.97	2.89 million shs	3.16 million shs
RLAY Relay Therapeutics	$18.19 -3.5%	$19.30	$4.32 ▼ $21.27	$3.99B	1.69	3.20 million shs	2.87 million shs
SMMT Summit Therapeutics	$16.90 -5.3%	$14.71	$12.07 ▼ $29.23	$13.48B	-1.24	4.38 million shs	5.77 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	-10.17%	-6.54%	+3.82%	+19.75%
BBIO BridgeBio Pharma	0.00%	-8.05%	-18.27%	-3.35%	+27.19%
RLAY Relay Therapeutics	0.00%	-0.16%	-3.09%	+9.03%	+304.29%
SMMT Summit Therapeutics	0.00%	+1.71%	+35.64%	+25.00%	-5.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$237.59 +0.4%	$254.83	$186.05 ▼ $282.15	$14.82B	0.35	694,892 shs	806,919 shs
BBIO BridgeBio Pharma	$66.58 0.0%	$79.31	$48.78 ▼ $93.42	$13.02B	0.97	2.89 million shs	3.16 million shs
RLAY Relay Therapeutics	$18.19 -3.5%	$19.30	$4.32 ▼ $21.27	$3.99B	1.69	3.20 million shs	2.87 million shs
SMMT Summit Therapeutics	$16.90 -5.3%	$14.71	$12.07 ▼ $29.23	$13.48B	-1.24	4.38 million shs	5.77 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	-10.17%	-6.54%	+3.82%	+19.75%
BBIO BridgeBio Pharma	0.00%	-8.05%	-18.27%	-3.35%	+27.19%
RLAY Relay Therapeutics	0.00%	-0.16%	-3.09%	+9.03%	+304.29%
SMMT Summit Therapeutics	0.00%	+1.71%	+35.64%	+25.00%	-5.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	30.79% Upside
BBIO BridgeBio Pharma	2.83	Moderate Buy	$102.61	54.12% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	42.48% Upside
SMMT Summit Therapeutics	2.47	Hold	$25.91	53.30% Upside

Current Analyst Ratings Breakdown

Latest RLAY, ASND, BBIO, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00
9/15/2026	ASND Ascendis Pharma A/S	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$287.00
9/10/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
9/10/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$344.00
9/10/2026	ASND Ascendis Pharma A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/9/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/8/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$33.00
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	18.19	N/A	N/A	($2.97) per share	-80.00
BBIO BridgeBio Pharma	$713.07M	18.25	N/A	N/A	($10.77) per share	-6.18
RLAY Relay Therapeutics	$10.35M	385.14	N/A	N/A	$3.27 per share	5.56
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	18.43	26.79	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest RLAY, ASND, BBIO, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/19/2026	Q3 2026	SMMT Summit Therapeutics	-$0.28	N/A	N/A	N/A	$0.07 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
BBIO BridgeBio Pharma	N/A	1.23	1.17
RLAY Relay Therapeutics	N/A	18.27	18.27
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
RLAY Relay Therapeutics	96.98%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	14.23%
RLAY Relay Therapeutics	5.04%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

RLAY, ASND, BBIO, and SMMT Headlines

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.8% - Should You Sell?

3 hours ago | marketbeat.com

Engineers Gate Manager LP Makes New Investment in Summit Therapeutics PLC $SMMT

September 20 at 3:12 AM | marketbeat.com

Summit Therapeutics: It's Okay Not To Have An Answer

September 17, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)

September 15, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?

September 15, 2026 | marketbeat.com

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15, 2026 | businesswire.com

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

September 13, 2026 | streetinsider.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...

September 13, 2026 | streetinsider.com

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

September 13, 2026 | msn.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

September 13, 2026 | gurufocus.com

September 13, 2026 | businesswire.com

Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT

September 12, 2026 | marketbeat.com

Summit Therapeutics PLC (SMMT)

September 10, 2026 | fr.investing.com

Summit Therapeutics Shares Rise After Upgrade From Jefferies

September 9, 2026 | marketscreener.comM

Summit Therapeutics shares gain after Jefferies upgrades stock to buy

September 9, 2026 | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?

September 9, 2026 | marketbeat.com

Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP

September 9, 2026 | marketbeat.com

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

September 8, 2026 | insidermonkey.com

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

September 7, 2026 | insidermonkey.com

Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, ASND, BBIO, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$237.59 +0.87 (+0.37%)

As of 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$66.58 -0.03 (-0.05%)

As of 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Relay Therapeutics NASDAQ:RLAY

$18.19 -0.65 (-3.45%)

As of 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$16.90 -0.95 (-5.32%)

As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLAY, ASND, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLAY, ASND, BBIO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLAY, ASND, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, ASND, BBIO, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Relay Therapeutics NASDAQ:RLAY

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLAY, ASND, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLAY, ASND, BBIO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLAY, ASND, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, ASND, BBIO, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Relay Therapeutics NASDAQ:RLAY

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools